LeMaitre Vascular, Inc. (NASDAQ:LMAT) is Copeland Capital Management LLC’s 4th Largest Position

Copeland Capital Management LLC increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,163,392 shares of the medical instruments supplier’s stock after purchasing an additional 11,318 shares during the period. LeMaitre Vascular comprises about 1.9% of Copeland Capital Management LLC’s investment portfolio, making the stock its 4th biggest holding. Copeland Capital Management LLC owned 5.18% of LeMaitre Vascular worth $108,068,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 0.4% in the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier’s stock worth $159,747,000 after buying an additional 8,584 shares during the period. Vanguard Group Inc. lifted its stake in LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after acquiring an additional 4,964 shares in the last quarter. Driehaus Capital Management LLC boosted its position in LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares during the period. Summit Creek Advisors LLC grew its stake in LeMaitre Vascular by 0.6% during the 1st quarter. Summit Creek Advisors LLC now owns 229,936 shares of the medical instruments supplier’s stock valued at $15,259,000 after acquiring an additional 1,435 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of LeMaitre Vascular by 0.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 215,841 shares of the medical instruments supplier’s stock valued at $17,759,000 after purchasing an additional 1,520 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on LMAT. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. JMP Securities lifted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Barrington Research reaffirmed an “outperform” rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research note on Friday, September 20th. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Finally, StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.67.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $88.62 on Tuesday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $93.32. The company’s fifty day moving average price is $89.03 and its two-hundred day moving average price is $81.77. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of 58.69, a PEG ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter in the prior year, the firm posted $0.37 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.72%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.